Welcome to our dedicated page for Progyny news (Ticker: PGNY), a resource for investors and traders seeking the latest updates and insights on Progyny stock.
Progyny, Inc. (NASDAQ: PGNY) delivers innovative fertility and family-building benefits through integrated medical solutions and data-driven care models. This dedicated news hub provides investors and benefits professionals with essential updates on the company’s strategic initiatives, clinical advancements, and market leadership in employer-sponsored reproductive health solutions.
Access real-time announcements covering earnings reports, provider network expansions, and partnerships with Fortune 500 employers. Our curated feed includes analysis of PGNY’s patented Smart Cycle methodology, digital health platform developments, and regulatory updates impacting the fertility benefits sector.
Key content categories include quarterly financial results, clinical outcome studies, executive leadership changes, and coverage of emerging trends in assisted reproductive technology. Bookmark this page for streamlined access to PGNY’s latest progress in redefining fertility care through value-based models and patient-centric innovation.
Progyny, a leading provider of fertility and family building benefits, announced that CEO Pete Anevski will speak at the Jefferies Global Healthcare Conference. The event will take place on June 5, 2024, at 9:00 A.M. Eastern Time. The session will be accessible via a live audiocast, with a replay available on the company's website.
Progyny (Nasdaq: PGNY) announced a new share repurchase program to buy back up to $100 million of its common stock. This follows a previous program announced on February 29, 2024. The repurchase will be funded via existing cash balances and carried out through open market transactions, which may include Rule 10b5-1 plans under the Securities Exchange Act of 1934. The program's execution will depend on various factors such as stock price and market conditions. The company has the discretion to suspend or discontinue the program at any time, with no guaranteed amount of shares to be repurchased or specific prices disclosed.
Progyny (Nasdaq: PGNY), an innovative provider of fertility, family building, and women's health benefits, announced participation in two key healthcare conferences. On May 15, 2024, at 5:00 PM PT / 8:00 PM ET, Progyny executives will join a fireside chat at the BofA Securities 2024 Healthcare Conference. Additionally, they will partake in the Leerink Partners Healthcare Crossroads Conference on May 29, 2024, at 1:00 PM CT / 2:00 PM ET. Live audiocasts and replays will be accessible via the Events and Presentations section on the company’s website.
Progyny, Inc. announced strong Q1 2024 results with revenue of $278.1 million, a 7.6% increase from Q1 2023. Gross profit rose to $62.4 million, and net income was $16.9 million. The company saw an increase in clients and covered lives, leading to growth in fertility benefit and pharmacy benefit services revenue. Adjusted EBITDA was $50.3 million, with an 18.1% margin. Cash flow improved, and the company repurchased shares worth $26.4 million. The outlook for 2024 includes revenue of $1.23-$1.27 billion, net income of $68.4-$75.4 million, and Adjusted EBITDA of $216-$226 million.
FAQ
What is the current stock price of Progyny (PGNY)?
What is the market cap of Progyny (PGNY)?
